AGP Executive Report

Population Cap Referendum (Health & Services): Swiss voters head to the polls on June 14 on a proposal to cap Switzerland’s permanent resident population at 10 million by 2050, with “emergency measures” triggered once the country hits 9.5 million—supporters say it’s about easing pressure on housing, transport, and public services, while opponents warn it could harm access to healthcare staffing and strain EU ties. Sleep-Health Breakthrough: Swiss researchers report a first direct, non-invasive saliva-based molecular method to detect acute sleep deprivation, aiming to move fatigue assessment beyond self-reports and toward practical on-site testing. World Cup, Switzerland in the Spotlight: Qatar held Switzerland 1-1 with a stoppage-time equaliser from Boualem Khoukhi after Switzerland converted a first-half Breel Embolo penalty—leaving Group B wide open and raising the stakes for Switzerland’s next match. Humanitarian Safety (Global, With Swiss Relevance): A new report describes a sustained crackdown by Houthi forces on humanitarian and civil society workers, including raids, abductions, and detention, as part of a broader effort to restrict independent activity.

Swiss Referendum Watch: Switzerland votes June 14 on a “No to 10 million” population cap, with “free movement” with the EU potentially at stake and critics warning it could deter needed talent in healthcare and pharma. Biodiversity in Switzerland: Davos hosts the World Biodiversity Forum (June 14–19), with Swiss researchers saying global targets are not on track and biodiversity remains under severe pressure locally. Public Health & Safety: WHO warns Ebola in DR Congo is spreading into new areas, with isolation capacity lagging and hundreds of confirmed cases since mid-May. Diabetes Treatment: The FDA grants accelerated approval to teplizumab (Tzield) for children aged 8–17 newly diagnosed with stage 3 type 1 diabetes, aiming to delay loss of insulin production. Work & Health: The ILO adopts a new platform-economy labour standard in Geneva, covering occupational safety and health, fair pay, social protection, and data protections for gig workers. Swiss Economy & Pharma Links: India’s Piyush Goyal visits Switzerland to push the India-EFTA TEPA trade and economic partnership, including pharma investment discussions. Tech & Wellness: Swiss researchers report fatigue detection in saliva, adding to growing interest in simple biological signals for health monitoring.

Public Health: WHO warns Ebola in northeastern DR Congo is spreading into new areas, with 676 confirmed cases and 136 deaths since May 15; isolation capacity is far below what’s needed, and cases are increasingly showing local community spread. Swiss Politics & Health Access: Switzerland votes Sunday on a constitutional population cap at 10 million, a move opponents say could tighten asylum and family-reunification rules and strain services, while supporters argue it’s needed for housing, transport and public capacity. Sleep & Safety in Switzerland: University of Zurich researchers report saliva biomarkers that can directly detect acute sleep deprivation from a single sample—aimed at improving road safety and monitoring in high-risk jobs. Mental Health & Work: New research links working from home with higher isolation and worse mental health, especially for people living alone, while suggesting choice may matter more than forcing office work. Health Tech/Pharma (Switzerland-linked): Swiss pharma and biotech are in focus as India’s commerce minister Piyush Goyal visits to advance the India-EFTA TEPA, including cooperation with leading Swiss companies. Ecosystem/Climate: A report highlights how plastic pollution is tied to fossil-fuel use, with plastic production projected to drive major oil demand growth.

Asylum Policy Clash: A Swiss parliamentary committee wants to tighten asylum removal rules by listing fixed grounds where deportation is “unreasonable,” narrowing discretion to war, civil war, general violence or a medical emergency—sparking pushback from associations and organisations. Population Cap Fallout: Swiss voters face a referendum on capping the population at 10 million by 2050; pharma groups warn it could restrict access to skilled workers and disrupt hiring, with exports and foreign talent central to the sector’s future. Basel Pharma Anxiety: A Reuters report highlights Basel’s dependence on international pharma talent and warns the cap could create uncertainty for major employers and strain EU ties. Novartis Trial Update: Novartis reports a phase 1/2 win for its dystrophy drug from the Avidity deal, moving it closer to regulatory talks for facioscapulohumeral muscular dystrophy. Allergy & Asthma Push: EAACI calls for “Vision Zero” to eliminate the allergy and asthma burden, framing prevention and coordinated policy as the next step. Humanitarian Access in Sudan: MSF Switzerland describes extreme barriers to reaching people in need amid Sudan’s conflict, with aid workers facing rising risks. Food Supply Pressure: A Swissinfo piece says Spain’s tomato and produce dominance is eroding as wages, regulations and non-European competition rise. Trade Diplomacy: India’s commerce minister Piyush Goyal is set to visit Bern to discuss the India-EFTA TEPA rollout, including with Swiss pharma leaders.

Swiss Health Policy: Switzerland’s June 14 referendum would cap the population at 10 million, with critics warning it could squeeze the economy by limiting access to skilled workers and straining relations with the EU. Mental Health: A new global ranking puts Switzerland among the higher-depression-rate countries in 2026 (estimated 6.05%), highlighting how mental health burden varies with conflict, isolation, and access to care. Public Health & Skin Safety: The US FDA has approved bemotrizinol, a sunscreen ingredient already used in Europe and Asia, aiming to boost consumer confidence and expand options with broad UVA/UVB protection. Healthcare Innovation (Switzerland-linked): Alp Bio, a Switzerland-based startup, says its AI plus lab-grown immune tissue approach can flag drug immune reactions earlier in development. Pharma & Trade: India’s commerce minister Piyush Goyal is set to visit Bern to push implementation of the India–EFTA TEPA, including talks with Swiss pharma leaders. Wellbeing & Research: World Aquatics reports an A1 governance rating after reforms, citing integrity, safeguarding, and athlete representation—framing sport as a health and social benefit.

Psilocybin in Routine Care: A University of Zurich-led real-world study in The Lancet Regional Health found psilocybin sessions for treatment-resistant depression were linked to clinically meaningful symptom improvements, including in patients often excluded from trials. Swiss Health Policy: Switzerland votes Sunday on tighter rules for conscientious objection to military service, with critics warning it could make civilian service harder to access—an issue that can affect healthcare and social-sector staffing. Population Pressure Debate: Another Swiss referendum, the “No to 10 million” plan, is framed by opponents as a response to government under-preparing for growth that strains housing, healthcare, transport, and schools. Biosimilars in Immunology: A new EU-focused report says biosimilars now make up about 70% of biologic medicine volume in immunology care, expanding access for millions. Biotech Workforce Watch: May saw a sharp rise in pharma/biotech layoffs, with Takeda and BioNTech among the biggest contributors. Swiss Pharma/Diagnostics Moves: Roche’s VENTANA MMR Rxdx panel companion diagnostic received IVDR approval across multiple cancer types, supporting broader clinical use. Wellness & Sun Safety: The FDA approved bemotrizinol, a sunscreen filter long used in Europe and Asia, aiming to restore consumer confidence and improve product options.

Swiss Health Policy & Society: Switzerland’s population-cap referendum (“No to a Switzerland of 10 Million”) is set for Sunday, with supporters backing tighter immigration and opponents warning it could disrupt housing, family reunification and freedom-of-movement rules. Public Health & Prevention: The FDA approved bemotrizinol (BEMT), a sunscreen active already used in Europe, aiming to boost protection and consumer confidence after years of limited new filters in the US. Infection & Wound Care Research: Scientists are exploring light-activated nanomaterials to fight hard-to-treat, antibiotic-resistant wound infections—especially for diabetic ulcers and chronic wounds. Sleep Safety: Researchers at the University of Zurich say they’ve found a saliva pattern that can detect dangerous sleep deprivation, potentially helping prove impairment in cases of tired driving. Wellbeing & Lifestyle: Marriott completed its Lefay wellness deal, adding a luxury wellness brand focused on movement, nutrition and preventative health expertise. Health Innovation (Cancer): VERAXA Biotech’s Zurich-based cancer therapy company has completed its merger and is set to begin trading on Nasdaq under new tickers.

Swiss Politics & Health Governance: A health workers’ group in the Philippines has urged Switzerland-linked scrutiny of a Geneva trip, calling for an Ombudsman investigation into Health Secretary Teodoro Herbosa and Undersecretary Albert Domingo over a business-class upgrade for a World Health Assembly trip. Swiss Health & Wellness: A Swiss-focused wildlife health update from WWF reports congenital heart malformations in lynx and highlights road/rail accidents as major causes of death, raising concerns about genetic diversity and long-term survival. Food & Nutrition: New coverage revives research that banana-and-berry smoothies can reduce flavanol absorption by 84%, with implications for everyday diet choices. Public Health & Aging: Elder Abuse Awareness Month is marked again, with reminders that abuse can be physical, emotional, sexual, or financial—and that neglect counts too. Health Tech & Pharma: Nxera Pharma joins OpenFold, an open AI consortium aimed at accelerating AI-enabled drug discovery, while Switzerland’s pharma automation congress AUTOMA+ 2026 in Zürich spotlights the gap between digital ambitions and real-world factory execution. Swiss Economy & Health Access: A major Swiss referendum on capping the population at 10 million is set for a vote, with critics warning it could strain sectors including healthcare.

Health & Travel: San Francisco public health issued a World Cup summer advisory warning of higher risks for imported infections like measles, typhoid and tuberculosis, plus heat illness and other threats as millions of visitors arrive across the US/Canada/Mexico. Policy & Care Access: Ireland’s government pushed for faster access to the first treatment for Friedreich’s Ataxia, with officials aiming to get the drug considered at upcoming HSE pricing and reimbursement meetings. Health Governance Scrutiny: A Philippines health workers’ group urged an Ombudsman probe into alleged “luxury” business-class upgrades for DOH officials traveling to Geneva for the World Health Assembly, arguing it may violate travel rules and anti-graft law. Global Health & Conflict: A UN inquiry said Palestinian civilians are trapped between mass atrocities by Israeli forces and settlers and Hamas’s repression, highlighting severe rights violations across Gaza and the West Bank. Nuclear Risk: ICAN and SIPRI reported record nuclear weapons spending and warned of a new arms race, with growing delivery readiness raising nuclear danger.

Swiss Health Policy & Workforce: Swiss business leaders and unions are mobilising ahead of Sunday’s vote on the SVP’s “No to a Switzerland with 10 million!” population cap, warning it could worsen labour shortages across sectors that rely on EU workers, including healthcare and construction. Geneva Health Diplomacy: Switzerland signed a declaration supporting the Gaza Strip, citing a near-collapse of public healthcare and rising skin infections amid restricted basic services. Clinical Research (Switzerland-linked): Oculis (Zug) says the first patient has been randomized in its genotype-based dry eye disease trial PREDICT-1 for licaminlimab targeting a specific TNFR1 group. Alzheimer’s Breakthrough (ETH Zurich): ETH Zurich researchers report an experimental compound (“Compound 10”) that slowed Alzheimer’s progression in mice by targeting a protective biology pathway. Pharma & Trials: Bial discontinued pariceract (BIA 28-6156) after a Phase 2b Parkinson’s study in GBA1 patients missed efficacy endpoints, though safety looked acceptable. Health Tech & Data Privacy: Custodia launched “Sentinel,” a local AI device for sensitive work that keeps data off the internet by processing documents on-device. Health & Society: A Swiss study finds sperm quality is steady, while another report highlights protein-repair defects linked to hidden heart failure.

Roche’s Big Bet on Cancer: Swiss pharma Roche agreed to pay Nurix Therapeutics up to $700M upfront (up to $2.3B total) to co-develop a late-stage targeted protein-degrading therapy, highlighting Switzerland’s continued push into next-gen oncology. Alzheimer’s Drug Discovery: Researchers report a new compound (“Compound 10”) that blocks GRK2 aggregation, aiming to slow Alzheimer’s progression by protecting mitochondria and delaying nerve cell death. Kidney Care Update: Vantive (Swiss-linked kidney innovation) presented late-breaking data suggesting HDx therapy with the Theranova dialyzer is non-inferior to online hemodiafiltration for key outcomes. Health Policy Scrutiny in Geneva: A health workers group asked the Ombudsman to investigate alleged “flight upgrades” for officials attending the World Health Assembly in Switzerland. Swiss Medical Diagnostics Access: GENFIT said its NASHnext® test (for at-risk MASH) is now available via Labcorp OnDemand, expanding physician-directed non-invasive screening. Sports & Health Context: Canada’s World Cup campaign took a hit with a defender ruled out due to lingering injury concerns.

Roche’s Cancer Bet: Swiss pharma Roche agreed a licensing and collaboration deal with California’s Nurix Therapeutics on bexobrutideg, a BTK degrader for chronic lymphocytic leukaemia, with $700m upfront and up to $2.3bn in milestones; Roche covers 60% of development and they co-commercialise in the US. Swiss Healthcare Staffing Pressure: A new survey says Swiss doctors’ average weekly working time fell to 54.6 hours, but fatigue is still “critical,” with 52% reporting they can’t do any more and about 60% saying fatigue has put patients at risk. Alzheimer’s Drug Lead: ETH Zurich researchers report “compound 10” slowed Alzheimer-like nerve-cell loss in mice, pointing to a possible new target involving GRK2. Care Access in Practice: Mpilo Central Hospital in Zimbabwe has begun installing new radiotherapy machines, aiming to restore and expand cancer treatment after long disruptions. Malaria Treatment Milestone: Africa CDC welcomed approval of Coartem Baby, a newborn-focused malaria medicine developed with Novartis, expected to roll out across multiple African countries. Nutrition Basics (Local Angle): A quick guide highlights Malabar spinach’s vitamin A/C, calcium and iron, plus ways to cook and store it.

Cancer Tech Upgrade: Mpilo Hospital in southern Africa has started installing new radiotherapy equipment, aiming to end years of broken service and “turning away” patients; the full rollout is expected to take about three months, with additional machines sourced from Switzerland. Swiss Health Policy & Care: Switzerland is preparing for a June 14 referendum on capping its population at 10 million by 2050, a vote that could reshape pressure on housing, transport, and public services—and affect EU free-movement dynamics. Mental Health & Aging: A study with the Kalasha Foundation (Switzerland) highlights loneliness, nutrition strain, and healthcare access gaps among elderly people in Nepal’s Upper Mustang, urging stronger community-based elderly care. Injury Prevention & Emergency Response: An avalanche killed one off-piste skier in Switzerland’s Titlis area; authorities raised avalanche warnings after heavy snowfall, while Austria reported power outages and road closures. Cardiovascular Health: A global analysis of lipid tests ranks South Korea lowest for LDL levels, while Austria and Germany top the highest-cholesterol list; Switzerland sits just below the highest group. Public Safety & Justice: Switzerland’s federal prosecutors say they still lack access to seized devices in a Winterthur stabbing case because the suspect contests the search.

Swiss Justice: In the Winterthur stabbing case, Switzerland’s Office of the Attorney General says it still can’t access the suspect’s laptop and mobile phone because he objects to the search, so prosecutors can’t yet map who he contacted or what was written. Obesity Drug Watch: At the American Diabetes Association meeting, Roche and Zealand highlighted tolerability for their amylin-based obesity drug petrelintide, reporting mostly mild gastrointestinal side effects and a reported 22.7% average weight loss in a mid-stage trial. Ebola Update: The WHO reports the central Africa Ebola outbreak is nearing 500 confirmed cases, with concern growing that it could become one of the largest on record without strong public health action. Sports & Health: Lionel Messi sat out Argentina’s pre-World Cup friendly with hamstring muscle fatigue/strain, while Switzerland’s Granit Xhaka spoke about leading the team at the 2026 tournament. Public Health & Care: Switzerland is taking steps to improve support for women with endometriosis, aiming to strengthen care pathways. Health Research (Switzerland): A Zurich study suggests Swiss recruits’ sperm quality is holding steady.

Ebola Watch: WHO reports nearly 500 confirmed Ebola cases in central Africa, with 452 cases and 82 deaths in the Democratic Republic of Congo and 19 cases in Uganda, as the outbreak grows and WHO warns it could become the largest on record without strong interventions. Swiss Healthcare Policy: The Swiss government approved a report calling for earlier diagnosis and better treatment of endometriosis, noting many women wait years for care and that current system gaps worsen pain, fatigue, anxiety and fertility challenges. Regulator vs Media: Neue Zürcher Zeitung (NZZ) is fighting Swissmedic in court after the regulator ordered deletions of articles it said were unauthorized advertising for prescription-only medicines, including weight-loss drug coverage. Sports & Health (Switzerland link): Tiger Woods is reportedly continuing rehab in Switzerland through the end of June while supporting girlfriend Vanessa Trump after her breast cancer diagnosis. Public Health & Safety: A Swiss-led project is highlighted for a potential treatment target in age-related macular degeneration, pointing to new avenues for eye health.

Swissmedic vs media: Neue Zürcher Zeitung (NZZ) is fighting Swissmedic in court after the regulator ordered deletions of articles it said were unauthorised advertising for prescription-only medicines, including a migraines piece and several weight-loss drug reports. Obesity drug race: Roche said its experimental dual-acting obesity drug enicepatide helped mid-stage patients lose 22.7% of body weight after 48 weeks, with no plateau signal at that point. Cannabis and hormones: A University of Geneva study in Swiss conscripts found regular cannabis use did not lower testosterone in young men and may even raise it, alongside proposed new hormonal markers of use. Assisted dying debate: A new discussion weighs assisted dying “for and against,” highlighting comfort for some patients, but also travel-related inequity and legal risks for helpers. Digital sovereignty: Swissinfo looks at whether Switzerland can truly distance daily life from Big Tech, after two journalists tried cutting ties with US tech giants. Dental health: Dentists warn that frequent seltzer sipping can erode enamel, especially when it’s consumed throughout the day rather than with meals. Swiss research spotlight: Zurich researchers report oxytocin rises during group competition, especially when rivals are familiar, with stronger effects noted in men.